Global RNA-based Therapeutics Market is valued at USD 12.4 Bn in 2024 and is predicted to reach USD 22.6 Bn by the year 2034 at a 6.5% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
RNA-based therapeutics is a moderately new class of treatment representing significant potential and growth for the treatment of severe and rare diseases. RNA-based therapeutics are gaining significance for several disease targets, such as genetic disorders, HIV, cancer, etc. The growing prevalence of chronic diseases and lack of proper treatment is generating high demand for the development of RNA-based therapeutics. For instance, according to WHO, cancer ranked number two as a cause of death, and about 9.6 million deaths occurred in 2018. Moreover, the rising prevalence of genetic diseases, hematological disorders are generating the global demand for RNA-based therapeutics. Moreover, advancements and development of promising technologies such as SMaRT technology, antisense technology, and RNAi interference technology are expected to generate immense opportunities for the growth of the market in the coming years.
The strong base on ongoing studies for RNA-based therapeutics and the presence of a large number of players investing in the market is estimated to propel the growth of the market significantly over the estimated timeframe. In July 2018, about 320 ongoing clinical studies for RNA-based therapeutics were registered. The introduction of these potential therapies in the coming years is expected to significantly boost the market's overall growth. However, challenges connected with the commercialization of RNA-based therapies such as drug delivery and toxicity may substantially hamper the market growth. Moreover, the high cost of development may hinder the growth of the market. The lack of substitute treatment selections for rare diseases further enhancing the demand for RNA-based therapeutics globally. Additionally, a growing focus of legislative bodies on evolving reimbursement policies is fueling the development of RNA’s molecules process.
The Global RNA-Based Therapeutics Market is segmented based on product, type, indication and end-user. By Product segment, the market is divided into Vaccines and Drugs. Whereas, By Type, the market is categorized into mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, RNA Aptamer, and Other Therapeutics. The segmentation includes Indication segment which is further classified into Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Oncology, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), and Others. The End User segment comprises Hospitals and Clinics, Research Settings.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 12.4 Billion |
| Revenue Forecast In 2034 | USD 22.6 Billion |
| Growth Rate CAGR | CAGR of 6.5% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Product, Type, Indication, End-User and Delivery Mechanism |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Biogen Inc., TME Pharma, IVERIC bio (Astellas Pharma), Olix Pharmaceuticals, GlaxoSmithKline Plc, Sanofi S.A, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma Ltd, Acuitas Therapeutics, Arbutus Biopharma, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Bio-Path Holdings Inc., Calando Pharmaceuticals (Arrowhead Pharmaceuticals Inc.), Percheron Therapeutics Limited, Gene Signal, Gradalis, iCo Therapeutics, Aptose Biosciences, Viridian Therapeutics, Inc., Mirna Therapeutics Inc (Synlogic, Inc.), Adhera Therapeutics, Achieve Life Sciences, Inc., Syntara Limited, Rexahn Pharmaceuticals (Ocuphire Pharma, Inc.), Regulus Therapeutics (Novartis), Phio Pharmaceuticals Corp., Santaris Pharma A/S (Roche), Sarepta Therapeutics, Sirnaomics Inc., Dicerna Pharmaceuticals (Novo Nordisk), Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global RNA-based Therapeutics Market Snapshot
Chapter 4. Global RNA-based Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global RNA-based Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on RNA-BASED THERAPEUTICS MARKET Industry Trends
Chapter 5. RNA-based Therapeutics Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Vaccines
5.2.2. Drugs
Chapter 6. RNA-based Therapeutics Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Infectious Diseases
6.2.2. Rare Genetic Diseases/Hereditary Diseases
6.2.3. Oncology
6.2.4. Ophthalmology
6.2.5. Hematological Disorders
6.2.6. Acute Hepatic Porphyria (AHP)
6.2.7. Others
Chapter 7. RNA-based Therapeutics Market Segmentation 3: By Type, Estimates & Trend Analysis
7.1. Market Share by Type, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
7.2.1. mRNA Therapeutics
7.2.2. RNA Interference (RNAi) Therapeutics
7.2.3. Antisense Oligonucleotide (ASO) Therapeutics
7.2.4. RNA Aptamer
7.2.5. Other Therapeutics
Chapter 8. RNA-based Therapeutics Market Segmentation 4: By Delivery Mechanism, Estimates & Trend Analysis
8.1. Market Share by Delivery Mechanism, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Mechanism:
8.2.1. Lipid Nanoparticles (LNPs)
8.2.2. Polymer-Based Nanoparticles
8.2.3. Viral Vectors
8.2.4. Naked RNA
Chapter 9. RNA-based Therapeutics Market Segmentation 5: By End-User, Estimates & Trend Analysis
9.1. Market Share by End-User, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:
9.2.1. Hospitals and Clinics
9.2.2. Research Settings
Chapter 10. RNA-based Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global RNA-based Therapeutics Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.2.3. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.2.4. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.2.5. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.2.6. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.3. Europe
10.3.1. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.3.3. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.3.4. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.3.5. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.3.6. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.4.3. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.4.4. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
10.4.5. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Delivery Mechanism, 2021-2034
10.4.6. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.5. Latin America
10.5.1. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.5.3. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.5.4. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.5.5. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.5.6. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.6.3. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.6.4. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.6.5. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.6.6. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Biogen Inc.
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Type
11.2.1.3. Financial PerProductance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. TME Pharma
11.2.3. IVERIC bio (Astellas Pharma)
11.2.4. Olix Pharmaceuticals
11.2.5. GlaxoSmithKline Plc
11.2.6. Sanofi S.A
11.2.7. Alnylam Pharmaceuticals
11.2.8. Ionis Pharmaceuticals
11.2.9. Benitec Biopharma Ltd
11.2.10. Acuitas Therapeutics
11.2.11. Arbutus Biopharma
11.2.12. Silence Therapeutics Plc
11.2.13. Enzon Pharmaceuticals Inc
11.2.14. Bio-Path Holdings Inc.
11.2.15. Calando Pharmaceuticals (Arrowhead Pharmaceuticals Inc.)
11.2.16. Percheron Therapeutics Limited
11.2.17. Gene Signal
11.2.18. Gradalis
11.2.19. iCo Therapeutics
11.2.20. Aptose Biosciences
11.2.21. Viridian Therapeutics, Inc.
11.2.22. Mirna Therapeutics Inc (Synlogic, Inc.)
11.2.23. Adhera Therapeutics
11.2.24. Achieve Life Sciences, Inc.
11.2.25. Syntara Limited
11.2.26. Rexahn Pharmaceuticals (Ocuphire Pharma, Inc.)
11.2.27. Regulus Therapeutics (Novartis)
11.2.28. Phio Pharmaceuticals Corp.
11.2.29. Santaris Pharma A/S (Roche)
11.2.30. Sarepta Therapeutics
11.2.31. Sirnaomics Inc.
11.2.32. Dicerna Pharmaceuticals (Novo Nordisk)
11.2.33. Others
RNA-based Therapeutics Market by Product-
RNA-based Therapeutics Market Based on Type-
RNA-based Therapeutics Market Based on Indication-
RNA-based Therapeutics Market Based on End-User-
RNA-based Therapeutics Market By Delivery Mechanism-
RNA-based Therapeutics Market Based on Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-